Bayer AG (FRA:BAYN) Receives €80.47 Consensus PT from Analysts
Bayer AG (FRA:BAYN) has earned a consensus rating of “Hold” from the twenty ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is €80.47 ($93.57).
Several analysts have commented on BAYN shares. Bank of America set a €95.00 ($110.47) price objective on Bayer and gave the company a “buy” rating in a report on Friday, September 13th. JPMorgan Chase & Co. set a €69.00 ($80.23) price objective on Bayer and gave the company a “neutral” rating in a report on Monday. Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer and gave the company a “buy” rating in a report on Monday. HSBC set a €63.00 ($73.26) price objective on Bayer and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Berenberg Bank set a €75.00 ($87.21) price objective on Bayer and gave the company a “neutral” rating in a report on Friday, November 1st.
Bayer stock traded down €0.18 ($0.21) during midday trading on Friday, hitting €70.25 ($81.69). 1,936,937 shares of the company were exchanged. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98). The business has a fifty day simple moving average of €66.89 and a two-hundred day simple moving average of €61.74.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.